Answer
Severe renal or hepatic impairment is contraindicated in the selected products. Lesser impairment increases hypoglycaemia risk and requires assessment and monitoring.
Sources for this answer
- Xywin 60 mg Prolonged-release Tablets Gliclazide — Current selected SmPCemc · Summary of Product Characteristics
- Gliclazide 80 mg Tablets 28's (POM) (PL 43461/0009) — Current selected SmPCemc · Summary of Product Characteristics